TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01567787

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation for MPNST
Description: 30 CGE at 6 CGE/Fx

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation for neurofibromas
Description: 25 CGE at 5 CGE/Fx
Study: NCT04237857

Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy
Study: NCT04263714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic exercise and resistance exercise
Study: NCT02325349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radiopharmaceutical (Flotegatide (18F) or RGD (68Ga)
Description: PET/CT after intravenous administration of 2-4MBq/kg of body weight of Flotegatide (18F) or RGD (68Ga) performed prior and after 2 cycles of chemotherapy including an agent with antiangiogenic effect (two examinations in each patient)
Study: NCT01630226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Cisplatin Chemotherapy
Description: Patients will be treated with cisplatin chemotherapy at a dose of 75mg/m2 every three weeks for a total of four cycles (4 cycles of neoadjuvant chemotherapy).
Study: NCT03389789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose solution + maternal holding
Description: Infant will receive both the oral glucose solution and the contact with the mother

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Description: Infants will be breastfed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose solution
Description: Infant will receive only oral glucose solution without contact with the mother

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral expressed breastmilk
Description: Infant will receive only oral expressed breast milk without contact with the mother
Study: NCT01370928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus PCF-Y0014-L
Description: Screening colonoscopy with a prototype colonoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard colonoscope
Description: Screening colonoscopy
Study: NCT01560494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STAC curriculum
Description: The STAC curriculum consists of theoretical preparation, case-based learning, proficiency-based virtual reality training, laparoscopic box training, and operating room participation.
Study: NCT03082313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement Intervention
Description: At each visit, the caregiver will be reminded of the infant's movement rate from the last visit. The research team will help the caregiver to determine possible ways to achieve the goal of 1200 movements per hour of awake time. Strategies to increase leg movements will be encouraged based on the infant's developmental level and what they demonstrate a response to, including: shake a toy when infant moves legs, sing a line of a song when infant moves legs, change the position of the infant to encourage more leg movement, or lightly tickle the legs and feet of the infant. The intervention will be based upon the GAME (Goals - Activity - Motor Enrichment) protocol, a motor learning, environmental enrichment intervention that has recently been shown to be effective for improving motor skills in infants at high risk of cerebral palsy compared to standard care.
Study: NCT02909959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane
Description: The investigational medicinal product is an uncoated tablet containing both glucoraphanin and myrosinase, the enzyme that converts glucoraphanin to sulforaphane in vivo. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets are uncoated and matched in appearance to the investigational medicinal product, containing inert components. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
Study: NCT04332094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 162 mg sc x 2 doses + tocilizumab 162mg sc x 2 doses at 12 hours (day 1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: 400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 500 mg / day v.o. for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500 mg / day v.o. for 3 days
Study: NCT01752959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 0.1-0.3 micg/kg/min Remifentanil iv infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: 500 μcg/kg/dk esmolol iv lading dose after 50-500 μcg/kg/dk esmolol iv infusion
Study: NCT03340909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone tablets initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start
Study: NCT02797587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 1 week starter kit followed by 1mg twice daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytisine
Description: Multi-daily dosing, range 3-9 mg daily for 25 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine Replacement Therapy
Description: Mouth spray dosing based on standard recommendations tapered over 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine Replacement Therapy
Description: Mouth spray dosing based on standard recommendations tapered over 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline Placebo
Description: 1 week starter kit followed by 1 pill twice daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytisine Placebo
Description: Multi-daily dosing for 25 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy Placebo
Description: Mouth spray dosing based on standard recommendations tapered over 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy Placebo
Description: Mouth spray dosing based on standard recommendations tapered over 8 weeks.
Study: NCT00753545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: Tablets Oral BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: matching placebo bid
Study: NCT02616276

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control breakfast
Description: It consists of 350 ml of water at room temperature.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control breakfast
Description: It consists of 350 ml of water at room temperature.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control breakfast
Description: It consists of 350 ml of water at room temperature.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High glycemic index breakfast
Description: It consists of 350 ml of water at room temperature, 200 ml of grape juice (with 136.28 kcal), 40 g of white bread (2 slices of 52.2 kcal each) and 29 g of strawberry jam (with 127.52 kcal); providing a total of 368.2 kcal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High glycemic index breakfast
Description: It consists of 350 ml of water at room temperature, 200 ml of grape juice (with 136.28 kcal), 40 g of white bread (2 slices of 52.2 kcal each) and 29 g of strawberry jam (with 127.52 kcal); providing a total of 368.2 kcal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High glycemic index breakfast
Description: It consists of 350 ml of water at room temperature, 200 ml of grape juice (with 136.28 kcal), 40 g of white bread (2 slices of 52.2 kcal each) and 29 g of strawberry jam (with 127.52 kcal); providing a total of 368.2 kcal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low glycemic index breakfast
Description: It consists of 350 ml of water at room temperature, a 150 g apple (with 81.12 kcal), a 125 g low-fat natural yogurt (with 56.10 kcal), 3 shelled walnuts (with 38.94 kcal per unit) and 17.5 g of 72% black chocolate (with 102 kcal); supplying a total of 356.04 kcal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic index breakfast
Description: It consists of 350 ml of water at room temperature, a 150 g apple (with 81.12 kcal), a 125 g low-fat natural yogurt (with 56.10 kcal), 3 shelled walnuts (with 38.94 kcal per unit) and 17.5 g of 72% black chocolate (with 102 kcal); supplying a total of 356.04 kcal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic index breakfast
Description: It consists of 350 ml of water at room temperature, a 150 g apple (with 81.12 kcal), a 125 g low-fat natural yogurt (with 56.10 kcal), 3 shelled walnuts (with 38.94 kcal per unit) and 17.5 g of 72% black chocolate (with 102 kcal); supplying a total of 356.04 kcal.
Study: NCT00978588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% hydroxyethyl starch 130/0.4 and 5% albumin
Description: Injection of 6% hydroxyethyl starch 130/0.4 and 5% albumin as priming solution for cardiopulmonary bypass

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 and 5% albumin
Description: Injection of 6% hydroxyethyl starch 130/0.4 and 5% albumin as priming solution for cardiopulmonary bypass
Study: NCT02861456

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Model of Care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternative Model of Care
Study: NCT01788605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramosetron
Study: NCT03958773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiovalve transfemoral Mitral valve system
Description: Cardiovalve System, comprised of: 1) Cardiovalve Implant; 2) Cardiovalve Delivery System (DS); 3) Cardiovalve Accessories.
Study: NCT01727570

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein (Immunocal®)
Description: The amount of Immunocal® whey protein the patient is required to take daily will be determined on an individual basis by the nutritionist according to the assessed protein deficit in the patient's diet.
Study: NCT01760226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R for DLBCL, PTLD, AND PMBCL
Description: Day 1: Rituximab IV~Days 1-4: After rituximab, etoposide, vincristine, and doxorubicin will be given in a vein over 96 hours as a continuous infusion.~Day 5: cyclophosphamide will be given in a vein~Days 1-5: prednisone given by mouth twice a day~G-CSF 5mcg/kg/day will be given under the skin from day 6 until ANC has improved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: CNS negative patients with high CNS risk DLBCL will receive age based, intrathecal dosing of MTX on days 1 and 5 of cycles 3 - 6 only.~CNS positive patients will receive age based, intrathecal (within the spinal fluid) MTX twice weekly for 2 weeks past the first negative cytology with a minimum of 4 weeks treatment. Then, weekly for 6 weeks and then every 4 weeks for 6 months.~DLBCL/PTLD/PMBCL CNS prophylaxis for cycles 3-6 ONLY if:~* 2+ extranodal sites~* elevated LDH,~* MYC rearrangement OR~* bone or marrow disease.~ALL OTHERS receive IT MTX cycles 3-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be given at 50mg/m2/day on days 1-4 of the first cycle of therapy (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be given at 10mg/m2/day on days 1-4 of the first cycle (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be given on days 1-4 of each cycle at 0.4mg/m2/day (dose based on patient height and weight).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (375mg/m2/dose) will only be given on Day 1 of each cycle prior to all the other chemotherapy agents. Dose is based on patient height and weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given on Day 5 of each cycle. In cycle 1, the dose will be 750 mg/m2 (based on patient height and weight), and the dose will be adjusted up or down for future cycles based on blood test results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be given by mouth at 60mg/m2/dose (based on height and weight) twice a day on days 1-5 of each cycle.
Study: NCT01134978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Order
Description: Blocked order - predictable~Random order - unpredictable
Study: NCT01152086

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mountain hiking in the Austrian and Bavarian Alps
Description: Regularly supervised physical exercise training program.~Duration over all: 9 weeks; Frequency: 2 times per week; Duration one training-unit: 3 hours;~Program:~* Endurance training (performed within 70-85% of the maximum heart rate)~* Short exercises before hiking (Mobilisation, Body and nature perception, ca. 5 min)~* Stretching after hiking (ca. 5 min)~* Short break at half-time (ca. 15 min)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mountain hiking in the Austrian and Bavarian Alps
Description: Regularly supervised physical exercise training program.~Duration over all: 9 weeks; Frequency: 2 times per week; Duration one training-unit: 3 hours;~Program:~* Endurance training (performed within 70-85% of the maximum heart rate)~* Short exercises before hiking (Mobilisation, Body and nature perception, ca. 5 min)~* Stretching after hiking (ca. 5 min)~* Short break at half-time (ca. 15 min)
Study: NCT00865774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantity Frequency Model
Description: The quantitative intervention involves emphasis on tracking and measuring the number of drinks on a weekly basis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targets Subjective Drunkenness
Description: Explores factors leading to drunkenness and alternative coping strategies for healthier function.
Study: NCT03021408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIRT + Treadmill
Description: PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill training twice per day, 5 times a week, for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIRT + Treadmill Plus
Description: PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill-plus training (with visual and auditory cues) twice per day, 5 times a week, for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIRT + Virtual Reality
Description: PD patients will undergo a 4-week MIRT. All patients in the MIRT+Virtual Reality (VR) group will undergo 10-minutes VR training with enhanced perceptions (visual, auditory, and haptic inputs), twice per day, 5 times a week, for 4 weeks.
Study: NCT03381846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MOHS micrographic surgery
Description: Mohs surgery is a precise surgical technique used to treat skin cancer. Thin layers of cancer-containing skin are progressively removed and examined microscopically until only cancer-free tissue remains.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wide local excision
Description: A surgical technique in which the skin cancer is excised along with 2-3 cm of clinically normal appearing surrounding tissue.
Study: NCT01561365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ottawa ankle rules
Description: Ottawa ankle rules implementation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ottawa ankle rules
Description: Ottawa ankle rules implementation
Study: NCT02313181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Limited Formula
Description: 10 milliliters (mL) Nutramigen fed to baby by syringe after each breastfeeding and discontinued at the start of mature milk production

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Continue exclusive breastfeeding unless otherwise directed by a health care provider
Study: NCT02016560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET Scan
Description: positron emission tomography (PET) scan of the brain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET Scan
Description: positron emission tomography (PET) scan of the brain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET Scan
Description: positron emission tomography (PET) scan of the brain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET Scan
Description: positron emission tomography (PET) scan of the brain
Study: NCT02744235

Intervention type: DEVICE
Group type: OTHER
Intervention: Polysomnography Data

Intervention type: DEVICE
Group type: OTHER
Intervention: Jawbone UP®

Intervention type: DEVICE
Group type: OTHER
Intervention: Fitbit Charge ®
Study: NCT04047498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alternating DBS
Description: Constant DBS will be changed to DBS that is up- and downmodulated alternating between the left and right stimulation side.
Study: NCT03853265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated dental office visit
Description: An immersive first-person point of view (POV) video simulation of the dental office in the three-dimensional environment (using a virtual reality headset) which allows participant to look around the room as they move down the hallways which is to be watched/experienced by the participant as often as possible between the initial visit and the follow up visit
Study: NCT02674152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Study: NCT00208611

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12 Supplementation
Description: 1000 micrograms daily
Study: NCT04171778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole food, plant-based diet
Description: The study diet is whole food, plant based defined as containing no animal products or refined grains or added oils, minimal use of any sweeteners, and, for the purposes of this study, on average containing no more than 15% calories from fat.

Intervention type: OTHER
Group type: OTHER
Intervention: whole food, plant-based diet
Description: The study diet is whole food, plant based defined as containing no animal products or refined grains or added oils, minimal use of any sweeteners, and, for the purposes of this study, on average containing no more than 15% calories from fat.
Study: NCT06001424

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: Frenkel's exercises for lower limb, Proprioceptive neuromuscular facilitation for upper limb in the form of rhythmic stabilization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: Frenkel's exercises for lower limb, Proprioceptive neuromuscular facilitation for upper limb in the form of rhythmic stabilization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: life kinetic exercises
Description: A multimodal training that combines coordinative, cognitive and visual tasks.
Study: NCT00720837

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visualase® Thermal Therapy System
Description: An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.
Study: NCT02590653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Lipid-lowering therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Lipid-lowering therapy
Study: NCT01760226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF will be given at 5 mcg/kg/day during each cycle, starting on day 6, until the patient's ANC (absolute neutrophil count) is greater than 5000/mcL past nadir.
Study: NCT01335867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Description: Vigabatrin escalated to 3 grams daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills
Study: NCT01619059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 5 mg, Once daily, Up to 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
Study: NCT04149158

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sinetrol® Xpur